Society for Clinical Research Sites (SCRS) and Fortrea Partner to Advance Collaboration in Clinical Research
DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) — The Society for Clinical Research Sites (SCRS) and Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), are pleased to announce Fortrea's sponsorship of the SCRS Collaborate Forward working group.
Comprising 16 leading Global Impact Partner organizations, the Collaborate Forward working group will explore and develop best practices to reduce administrative burdens across the clinical research ecosystem. The group is committed to fostering transparency and collaboration to tackle challenges faced by clinical research sites. By improving internal processes, it aims to make sites more sustainable and trials more efficient—ultimately leading to a smoother experience for patients.
Fortrea's sponsorship marks a significant investment in fostering industry-wide innovation and reflects the company's dedication to placing sites at the forefront of clinical trial planning.
'We are excited to partner with SCRS to launch and support this working group,' said Mike Clay, senior vice president of Global Project Delivery at Fortrea. 'Clinical trials are becoming increasingly complex, and the industry faces mounting pressure to accelerate innovation for patients. We believe that collaboration with clinical research sites is key to unlocking efficiencies and productivity gains that will streamline the clinical trial process. This initiative will develop tangible solutions that clinical study sponsors, CROs, vendors, sites and patient advocacy groups can rally behind. As a leading CRO, we are proud to be at the forefront of this effort, ensuring that sites remain central to driving progress and fostering greater industry-wide collaboration to bring life-changing treatments to patients faster.'
'Clinical research requires a unique interdependency to generate the best outcomes. Collaborate Forward will share partnership successes that impact the people, process and technology improving clinical research today,' added Sean Soth, senior vice president, Strategy and Global Business Partnerships, SCRS. 'We are pleased to welcome Fortrea as the charter sponsor of Collaborate Forward. This partnership underscores the value of cross-industry collaboration and the collective effort needed to drive meaningful progress in creating a more connected and efficient clinical trial ecosystem.'
Collaborate Forward will initially focus on study startup, showcasing the advantages of collaboration through compelling stories, case studies and data-driven insights. The group will convene regularly to exchange insights, assess industry trends and develop pragmatic tools that sponsors and CROs can implement within their organizations. Updates on the working group's progress will be shared throughout 2025 via SCRS Site Solutions Summits and publications, highlighting key findings and collaborative achievements.
SCRS invites sponsors and CROs committed to site sustainability to join this effort and contribute to shaping a more effective and synergistic clinical research landscape. For more information on how to participate, please contact Brian Egan.
About The Society for Clinical Research Sites
The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 11,000 research sites globally, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued. Learn more and get involved at myscrs.org. Our voice. Our community. Your success.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).
SCRS Contacts:
Fortrea Contacts:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Tribune
2 days ago
- Daily Tribune
Stocks extend gains on rate-cut bets
Stock markets rose yesterday, with Wall Street building on the previous day's record highs after steady US inflation data fuelled hopes that the US Federal Reserve will cut interest rates. The broad-based S&P 500 index and the tech-heavy Nasdaq extended gains after reaching new summits on Tuesday. Tokyo's Nikkei index followed suit on Wednesday, hitting a record as it closed 1.3% higher. European stock markets also finished in the green. Investors have worried about the impact that US President Donald Trump's tariffs will have on US inflation and growth in the world's biggest economy. But official figures showed Tuesday that the US consumer price index (CPI) remained steady at 2.7% in July, unchanged from June. Investors shrugged off data showing that core CPI -- a measure of inflation that strips out volatile food and energy prices -- accelerated in July to the fastest pace in six months to 3.1%. 'Even as core CPI was accelerating, markets were reassured because the tariff impact on inflation didn't look so obvious this time,' Deutsche Bank analysts said in a note. Markets could have reacted negatively as core inflation is usually the data point favoured by the Fed to make decisions on interest rates, said Ipek Ozkardeskaya, senior analyst at Swissquote Bank. 'Investors instead increased September cut expectations, thinking that imported goods inflation remained lower than feared as companies continued to absorb tariff costs,' she said. Trump has repeatedly demanded that the independent Fed cut rates and lambasted its chief, Jerome Powell, over the issue. The central bank, which will make its next interest-rate decision in September, has kept borrowing costs unchanged for now. The dollar slumped against other major currencies as the prospect of lower interest rates reduced its appeal to foreign investors. Investor focus was also on a summit in Alaska on Friday between Trump and Russian leader Vladimir Putin on the three-year-old Ukraine war. And oil prices fell more than 1% as the International Energy Agency raised its forecast for supply growth in 2025 and 2026 -- leaving the world with a surplus -- after OPEC+ decided to raise production.
Daily Tribune
30-07-2025
- Daily Tribune
Stock markets rise
Stock markets in the United States and Europe rose yesterday as investors turned their attention from trade deals to a slew of company results falling this week. New York's tech-heavy Nasdaq and the broad S&P 500 indices moved confidently higher out of the gate, though the Dow was struggling. London's FTSE, the CAC 40 in Paris and the DAX in Frankfurt were all trading higher, reversing dives a day earlier. The picture in Asia was mixed, though, with Shanghai closing higher but Hong Kong and Tokyo losing ground. The transatlantic bounce was different from Monday, when European indices closed in the red and US ones were muddled in the wake of the EU-US trade deal announced on the weekend. 'The fact that markets have bounced back today suggests investors have been buoyed by hopes that the US-EU trade accord might draw a line under recent uncertainty, offering European businesses a clearer path forward,' said Fawad Razaqzada, market analyst at Still, on the currency market, the euro extended losses against the dollar, indicating that European disgruntlement at the trade deal had not gone away. The euro has 'suffered a nasty battering... as investors questioned just how positive the US-EU trade deal was for the European Union', said David Morrison, senior market analyst at Trade Nation. Earning reports Tuesday's focus was now more on company earning reports that are raining down this week in the United States and Europe, with tech heavyweights in the spotlight. Meta and Microsoft were to give results on Wednesday, with Amazon and Apple following on Thursday. The massive investment race in artificial intelligence was informing much of the action. Bloomberg News reported that Microsoft was in talks to keep access to OpenAI technology, even if the ChatGPT maker achieves AI that goes beyond human intelligence. Meta, meanwhile, has opened its pockets wide to grab AI talent -- including several OpenAI employees -- to build out its own artificial intelligence operations. Amazon and Apple are also competing, though the latter is seen to be badly lagging so far. Thomas Mathews, a markets analyst at Capital Economics, said a continued rally in US stocks 'may depend especially heavily on 'big tech' profit results continuing to paint a positive picture, especially around AI'. 'With the worst of the risks around trade seemingly fading, we suspect there are fewer remaining obstacles to further investor enthusiasm for AI and its implications for US companies,' he said. London's FTSE was boosted in particular by heavyweight AstraZeneca after the drugmaker posted strong earnings. Shares in eyewear giant EssilorLuxottica jumped more than 6% on strong second-quarter results, topping the Paris CAC 40 index. Swedish music streamer Spotify's shares slid 7% after it reported an operating profit that far missed its target. The US Federal Reserve, meanwhile, was to begin Tuesday its two-day policy meeting under increasing pressure from President Donald Trump to slash rates, despite stubbornly high inflation. Oil prices extended Monday's rise after Trump shortened a deadline for Russia to end its war in Ukraine to August 7 or 9, following which he vowed to sanction countries buying its crude.
Daily Tribune
29-07-2025
- Daily Tribune
Dollar rises on EU-US trade deal but European stocks turn sour
The dollar jumped Monday on the back of the US-EU trade deal, but the main European stock markets fell, reflecting unease at terms viewed as lopsided. Frankfurt closed sharply down, as shares in German carmakers plunged. Paris dipped, while London -- outside the EU -- also receded. In New York, the S&P 500 and Nasdaq rose, while the Dow largely traded flat. While Brussels defended the deal it struck on the weekend as 'better than a trade war with the United States', several EU countries expressed unhappiness. European capitals saw the agreement's 15% tariffs on most EU exports to the United States -- but none on US ones to the EU -- as skewed. As part of the deal, President Donald Trump said the bloc had agreed to purchase '$750 billion worth of energy' from the United States, and make $600 billion in additional investments. 'While the deal has avoided a much worse outcome for now, it remains to be seen whether it will last,' cautioned Jack Allen-Reynolds, a eurozone economist at Capital Economics. With average US tariffs on EU imports now around 17%, 'we think this will reduce EU GDP by about 0.2%,' he said. He predicted that 'uncertainty is likely to remain high' because Trump 'could still change his mind even after the deal has been finalised and signed'. Oil prices rose strongly. That was partly on relief from the deal -- but also because Trump shortened a deadline for Russia to end its war in Ukraine to August 7 or 9, after which he vowed to sanction countries buying its crude. Monday also saw the start of a fresh round of trade negotiations between China and the United States ahead of August 12, when a 90-day truce between the economic superpowers is scheduled to end. Shares in European companies tracked the unease at the EU-US deal. Volkswagen, BMW and Porsche all shed more than three% as the implications of high tariffs on their exports to the United States sank in. In Paris, shares in Pernod Ricard, which exports wine and spirits to the United States, fell more than 3%. Shares in Dutch brewer Heineken -- the world's second-biggest beer-maker -- lost more than 8% in Amsterdam after it announced a drop in sales. Traders were prepared for a busy week in the United States, with a slew of corporate earnings reports -- including from Apple, Microsoft, Meta and Amazon -- and macro data readings coming their way giving indications about US jobs and growth. The Federal Reserve is expected to keep interest rates unchanged at its meeting this week, with investors focused on its outlook for the rest of the year given Trump's tariffs and recent trade deals. What did EU, US agree? Both sides confirmed there will be a 15-percent acrossthe-board rate on a majority of EU goods -- the same level secured by Japan this month. Most significantly, that means a tariff reduction for the EU auto sector from the 27.5 percent carmakers had been forced to pay. While 15 percent is much higher than pre-existing US tariffs on European goods -- averaging 4.8 percent -- it mirrors the status quo, with companies currently facing an additional flat rate of 10 percent imposed by Trump since April. The EU also agreed its companies would buy $750 billion of liquefied natural gas, oil and nuclear fuels from the United States -- split equally over three years -- to replace Russian energy sources. And it said it would pour $600 billion in additional investments in the United States -- based on the "investment intentions of private companies" in the bloc, a senior EU official explained. A White House factsheet said EU countries -- which recently pledged to ramp up defence spending within NATO -- "agreed to purchase significant amounts of US military equipment." But the EU official said arms procurement was not "agreed or discussed" -- suggesting Washington was alluding to purchases expected independently from the trade agreement. Will any goods be tarifffree? The White House said the deal involved 'the elimination of all EU tariffs on US industrial goods'. Brussels meanwhile said the leaders had agreed bilateral tariff exemptions for key goods -- with the exact list still to be finalised. The EU official said the bloc was ready to lower levies to zero percent on US cars, machinery products, some chemicals and items linked to fertilisers -- which could be an alternative to Russian sources. In exchange, the official said, Washington was expected to eliminate levies on European aircraft, certain medical devices and some pharmaceuticals for which the United States depends on EU imports. Discussions are ongoing about European alcohol exports becoming tariff-free -- including wine. The EU official also said the bloc would be willing to do away with levies on certain US products taxed at very low rates -- in the order of one to four percent -- including nuts, lobster, fish, dairy and pet food. Are there sector-specific terms? Semiconductors and pharmaceuticals are currently the target of US trade probes that could see Trump impose massive levies. Under the deal struck Sunday, the EU says the United States has agreed that whatever the outcome of those investigations, those sectors will not be taxed at more than 15 percent. The White House said pharmaceuticals and semiconductors would indeed be taxed at that rate. Protecting pharmaceuticals -- a major EU export to the United States and a critical sector for Ireland -- was a priority in the bloc's negotiations. Steel was another key area -- which along with copper and aluminium is currently facing a 50-percent US tariff. The White House said those sectoral tariffs 'will remain unchanged' but that it would 'discuss securing supply chains for these products' with the EU. But the EU official said the understanding was a certain quota of steel -- based on historic levels -- would enter the United States before the 50-percent levy kicks in. What happens next? The deal needs to be approved by EU states, under a process to be determined by what legal form the final agreement takes, the EU official said. On the US side, the majority of the undertakings are expected to be carried out by executive order. The EU had prepared a $109-billion retaliation package against US goods, which was due to take effect from August 7. Brussels will suspend the measures once Trump publishes his executive order.
